Compare Stocks → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGIONASDAQ:CINCNASDAQ:DCPHNASDAQ:DICE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$30.21+2.3%$29.66$19.80▼$35.50$1.70B0.83806,034 shs861,755 shsCINCCinCor Pharma$29.06-0.5%$29.08$10.53▼$43.15$1.27BN/A818,447 shs6.35 million shsDCPHDeciphera Pharmaceuticals$14.58-0.6%$15.66$9.90▼$17.73$1.18B0.39525,881 shs611,443 shsDICEDICE Therapeutics$47.55$47.31$15.08▼$47.90$2.27B1.031.03 million shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+2.30%+3.25%+1.10%+39.15%+33.20%CINCCinCor Pharma0.00%0.00%0.00%0.00%0.00%DCPHDeciphera Pharmaceuticals-0.61%-2.15%-4.27%+1.32%-0.95%DICEDICE Therapeutics0.00%0.00%0.00%0.00%+45.55%One trade. One ticker. One week. (Ad)Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals2.2546 of 5 stars2.32.00.04.71.20.80.0CINCCinCor PharmaN/AN/AN/AN/AN/AN/AN/AN/ADCPHDeciphera Pharmaceuticals3.3767 of 5 stars3.40.00.03.82.71.70.6DICEDICE TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals2.50Moderate Buy$33.5010.89% UpsideCINCCinCor PharmaN/AN/AN/AN/ADCPHDeciphera Pharmaceuticals2.80Moderate Buy$23.0057.75% UpsideDICEDICE Therapeutics2.22Hold$55.6717.07% UpsideCurrent Analyst RatingsLatest AGIO, DICE, CINC, and DCPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024AGIOAgios PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight3/20/2024DCPHDeciphera PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$14.00 ➝ $16.002/23/2024AGIOAgios PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$31.00 ➝ $30.002/16/2024AGIOAgios PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$43.00 ➝ $42.002/8/2024AGIOAgios PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/7/2024DCPHDeciphera PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $23.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$26.82M63.29N/AN/A$14.51 per share2.08CINCCinCor PharmaN/AN/AN/AN/A($1.74) per shareN/ADCPHDeciphera Pharmaceuticals$163.36M7.21N/AN/A$4.38 per share3.33DICEDICE Therapeutics$1.13M2,008.50N/AN/A$10.86 per share4.38Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$352.09M-$6.34N/AN/AN/A-1,312.64%-38.08%-33.69%5/2/2024 (Confirmed)CINCCinCor Pharma-$50.37M-$17.28N/AN/AN/AN/A-33.03%-27.21%N/ADCPHDeciphera Pharmaceuticals-$194.94M-$2.29N/AN/AN/A-119.33%-49.44%-38.41%5/1/2024 (Estimated)DICEDICE Therapeutics-$83.89M-$2.34N/AN/AN/AN/A-22.01%-20.79%N/ALatest AGIO, DICE, CINC, and DCPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2024N/AAGIOAgios Pharmaceuticals-$1.63N/A+$1.63N/AN/AN/A 2/15/2024Q4 2023AGIOAgios Pharmaceuticals-$1.64-$1.72-$0.08-$1.72$7.80 million$7.10 million 2/6/2024Q4 2023DCPHDeciphera Pharmaceuticals-$0.58-$0.54+$0.04-$0.54$45.93 million$48.30 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ACINCCinCor PharmaN/AN/AN/AN/AN/ADCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/ADICEDICE TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A12.2711.99CINCCinCor PharmaN/A51.9651.96DCPHDeciphera PharmaceuticalsN/A3.803.59DICEDICE TherapeuticsN/A25.8832.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ACINCCinCor Pharma99.15%DCPHDeciphera Pharmaceuticals70.96%DICEDICE TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.24%CINCCinCor Pharma15.60%DCPHDeciphera Pharmaceuticals4.43%DICEDICE Therapeutics4.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals38356.19 million53.81 millionOptionableCINCCinCor Pharma1543.76 million36.94 millionNot OptionableDCPHDeciphera Pharmaceuticals35580.80 million77.22 millionOptionableDICEDICE Therapeutics7147.73 million45.39 millionNot OptionableAGIO, DICE, CINC, and DCPH HeadlinesSourceHeadlineMinishoot' Adventures Hits Steam: A Bullet-Hell Bonanza with a Zelda Twistmsn.com - April 3 at 3:29 AMTop 5 Best Dice Tray in 2024straight.com - March 29 at 11:24 PMAvalo Snags Former Eli Lilly Asset and $185M in Major Pipeline Pivotbiospace.com - March 29 at 1:23 PMLee Avenue School fifth graders celebrate Pi Daymidislandtimes.com - March 28 at 4:57 PMVoyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easierseekingalpha.com - March 8 at 4:00 PMStoke City player ratings vs Cardiff as Potters sink into relegation zonemsn.com - February 24 at 5:46 PMMonopoly GO free dice rolls links (February 2024) – daily rewardsvideogamer.com - February 9 at 11:00 AMAbercrombie Announces Official Partnership With McLaren Racing, Features Race Car in Fifth Avenue Storees-us.finanzas.yahoo.com - January 31 at 1:15 PM15 Best Acne Treatment Products For Teens in 2024msn.com - January 30 at 10:10 PMStar Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officerfinance.yahoo.com - January 3 at 9:35 AMAltamira Therapeutics stock rises after it regains compliance with Nasdaqmsn.com - December 30 at 7:55 AMFree Monopoly GO Dice Links (December 2023)twinfinite.net - December 27 at 9:30 AMMonopoly GO Free Dice Rolls Links (December 2023)escapistmagazine.com - December 26 at 9:15 AMFree Monopoly Go dice links December 2023pcgamesn.com - December 3 at 11:16 PMPromise of new druggable targets drives Lilly into $660M Prism BioLab pactmmm-online.com - December 1 at 6:55 PMCan a Big Pharma Ever Be Worth $1 Trillion?msn.com - November 29 at 12:11 PMQ3 2023 Eli Lilly and Co Earnings Calluk.finance.yahoo.com - November 4 at 12:06 AMGLP-1 drugs carry Lilly, Novo; Moderna tops revenue expectationsmmm-online.com - November 2 at 3:32 PMEli Lilly to buy Dice Therapeutics for $2.4 billioninvesting.com - October 25 at 6:40 AMImmetas Therapeutics and GC Biopharma Announce Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseaseses-us.finanzas.yahoo.com - October 12 at 1:42 AMPoint Biopharma shares storm ahead 84% after Eli Lily's $1.4bn bidproactiveinvestors.com - October 3 at 12:25 PMIs Eli Lilly Stock A Buy Now That It Has Topped A Profit-Taking Zone?msn.com - September 29 at 5:30 PMConscious Re-Coupling: M&A Comes Back Surely, If Slowlygenengnews.com - September 23 at 8:23 AMWells Fargo Sticks to Their Hold Rating for Incyte (INCY)markets.businessinsider.com - September 11 at 6:52 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAgios PharmaceuticalsNASDAQ:AGIOAgios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.CinCor PharmaNASDAQ:CINCCinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.Deciphera PharmaceuticalsNASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.DICE TherapeuticsNASDAQ:DICEDICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.